Latest Conference Articles

Q&A: Ryan Kelly on What Good Supply Chain Audits Look Like

May 8th 2026

Ryan Kelly, Rx360, shares how aligning quality, supply chain functions, and auditing deeper is key to pharmaceutical patient safety.

Richard Sanderson on Why Modularization Is Key to Pharma Construction's Future

May 7th 2026

Richard Sanderson of IPS discusses risk management, predictive controls, and innovation to address skilled labor shortages in pharma construction.

Leslie Weaver and George Hunt on Scaling Lean and Sustainable Design

May 6th 2026

Leslie Weaver and George Hunt, IPS, explore how design for disassembly and lean thinking are transforming the way pharmaceutical facilities are built and scaled.

Q&A: Avi Nandi on Media and Buffer Supply Chain Strategies for CDMOs

May 5th 2026

Avi Nandi, SK Pharmteco, discusses how on-site media and buffer manufacturing can simplify supply chains and de-risk cell and gene therapy production.

Q&A: Christa Myers and Todd Vaughn Discuss Robotics in Aseptic Manufacturing

May 5th 2026

Todd Vaughn and Christa Myers of CRB discuss how robotics are reshaping aseptic pharmaceutical manufacturing, improving efficiency, repeatability, and compliance while demanding new operator skills and capital investment.

A Risk-Based Framework for Excipient Development

May 4th 2026

In part 4 of a multi-part series, David Schoneker, president, Black Diamond Regulatory Consulting, gives a preview of the workshop, Risk Based Framework for Development of New Excipient Products, at Excipient World 2026.

Maria Batalha on How Pharma Leaders Are Centralizing Drug Lifecycle Data

May 3rd 2026

Maria Batalha, Valgenesis, discusses how a centralized digital platform unified drug substance data from R&D to commercial manufacturing, enabling smarter, FAIR-compliant pharma operations.

Ryan Kelly's Tips for Drug Supply Chain Protection

May 2nd 2026

Ryan Kelly, Rx360, shares expert strategies for mapping, auditing, and protecting pharmaceutical supply chains to ensure global patient safety.

Excipients and Intended Use

May 1st 2026

In part 3 of a multi-part series, David Schoneker, president, Black Diamond Regulatory Consulting, talks about the collaboration between the pharma company and the excipient supplier when different routes of administration are considered for an ingredient.

Avi Nandi on the Impacts of On-Site Media and Buffer Manufacturing

May 1st 2026

Avi Nandi, SK Pharmteco, explores the benefits, challenges, and sustainability impact of on-site media and buffer manufacturing for cell & gene therapy.